Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Sarah Wiblin"'
Autor:
Iva Trenevska, Amanda P Anderson, Carol Bentley, Tasneem Hassanali, Sarah Wiblin, Shaun Maguire, Francesco Pezzella, Alison H Banham, Demin Li
Publikováno v:
PLoS ONE, Vol 16, Iss 4, p e0249967 (2021)
T-cell receptor mimic (TCRm) antibodies have expanded the repertoire of antigens targetable by monoclonal antibodies, to include peptides derived from intracellular proteins that are presented by major histocompatibility complex class I (MHC-I) molec
Externí odkaz:
https://doaj.org/article/9ac3c2ac2ee84090b0a591c24d8b6a6d
Autor:
Demin Li, Carol Bentley, Jenna Yates, Maryam Salimi, Jenny Greig, Sarah Wiblin, Tasneem Hassanali, Alison H Banham
Publikováno v:
PLoS ONE, Vol 12, Iss 4, p e0176642 (2017)
Therapeutic monoclonal antibodies targeting cell surface or secreted antigens are among the most effective classes of novel immunotherapies. However, the majority of human proteins and established cancer biomarkers are intracellular. Peptides derived
Externí odkaz:
https://doaj.org/article/31aed34546f24c8981f2b91c934d61df
Autor:
Alison H. Banham, Mark S. Cragg, Bart Cornelissen, Benedikt M. Kessler, Nicola Ternette, Iva Trenevska, Marloes Olde Nordkamp, Jenny Greig, Jenna Yates, Tasneem Hassanali, Sofia Koustoulidou, Kirstie L.S. Cleary, Sarah Wiblin, Amanda Anderson, Carol Bentley, Demin Li
The tumor suppressor p53 is widely dysregulated in cancer and represents an attractive target for immunotherapy. Because of its intracellular localization, p53 is inaccessible to classical therapeutic monoclonal antibodies, an increasingly successful
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6ad45d5e1ad71de4423b965173872613
https://doi.org/10.1158/0008-5472.c.6508499.v1
https://doi.org/10.1158/0008-5472.c.6508499.v1
Autor:
Alison H. Banham, Mark S. Cragg, Bart Cornelissen, Benedikt M. Kessler, Nicola Ternette, Iva Trenevska, Marloes Olde Nordkamp, Jenny Greig, Jenna Yates, Tasneem Hassanali, Sofia Koustoulidou, Kirstie L.S. Cleary, Sarah Wiblin, Amanda Anderson, Carol Bentley, Demin Li
Supplemental Materials and Methods from Development of a T-cell Receptor Mimic Antibody against Wild-Type p53 for Cancer Immunotherapy
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::146962e10f0ef1461cb29601c26a6b8a
https://doi.org/10.1158/0008-5472.22412708.v1
https://doi.org/10.1158/0008-5472.22412708.v1
Autor:
Alison H. Banham, Mark S. Cragg, Bart Cornelissen, Benedikt M. Kessler, Nicola Ternette, Iva Trenevska, Marloes Olde Nordkamp, Jenny Greig, Jenna Yates, Tasneem Hassanali, Sofia Koustoulidou, Kirstie L.S. Cleary, Sarah Wiblin, Amanda Anderson, Carol Bentley, Demin Li
Suppl Table 1: Quantitation of T1-116C binding sites per target cell; Suppl Figure 1: Validation of the HLA-A2/p53RMP tetramer; Suppl Figure 2: ELISA screening of HLA-A2/p53RMP tetramer-reactive TCRm hybridoma supernatants; Suppl Figure 3: T1-116C st
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b2c14b26228e504b028a1549db709d9c
https://doi.org/10.1158/0008-5472.22412711.v1
https://doi.org/10.1158/0008-5472.22412711.v1
Autor:
Iva Trenevska, Nicola Ternette, Mark S. Cragg, Tasneem Hassanali, Bart Cornelissen, Marloes Olde Nordkamp, Benedikt M. Kessler, Kirstie L. S. Cleary, Demin Li, Amanda Anderson, Sofia Koustoulidou, Jenna Yates, Alison H. Banham, Jenny Greig, Sarah Wiblin, Carol Bentley
Publikováno v:
Cancer Research. 77(10)
The tumor suppressor p53 is widely dysregulated in cancer and represents an attractive target for immunotherapy. Because of its intracellular localization, p53 is inaccessible to classical therapeutic monoclonal antibodies, an increasingly successful